Tabula Rasa HealthCare’s SinfoníaRx Releases RxCompanion™ 10.0 Software

MOORESTOWN, N.J., July 23, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ:TRHC), a healthcare technology company optimizing medication safety, today announced a new generation of proprietary software, RxCompanion™ 10.0, developed by the Company’s subsidiary, SinfoníaRx. The new version enhances TRHC’s medication management solutions used by health plans, health systems, provider organizations, and pharmacies.

RxCompanion™, first introduced in 2008, advances the delivery of clinical services, helping to minimize program costs while maximizing program outcomes. The 10.0 installment introduces a number of targeted enhancements focused on optimizing the user experience as demonstrated in the software’s robust quality-control measures and intuitive automation capabilities. Through a re-imagined system interface, RxCompanion^TM 10.0 provides users with all-new safeguard provisions and refined documentation enhancements, including immediate clinical feedback and automatic population of conditional fields.

“For more than ten years, RxCompanion™ has been an industry-leading software solution, utilizing hundreds of clinical algorithms to identify, predict and prevent medication-related problems,” said Dirk Timmermann, SinfoníaRx’s Vice President of Information Technology. “The RxCompanion™ 10.0 enhancement builds on this depth of powerful analytic capabilities, presenting our users with a unique platform for patient engagement and real-time results.”

In addition to SinfoníaRx’s comprehensive full-service model, RxCompanion™ 10.0 also is offered as a stand-alone and hybrid software solution supported by SinfoníaRx’s expert clinical support.

To learn more, visit and .

About Tabula Rasa Healthcare

Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs, and manage risk.  Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers, and other healthcare organizations. For more information, visit: .

About SinfoníaRx

SinfoníaRx, a Tabula Rasa HealthCare Company, is a leading provider of Medication Therapy Management (MTM) services. Through a comprehensive suite of innovative healthcare solutions, SinfoníaRx provides direct support to health plans, health systems, provider organizations, and pharmacies. SinfoníaRx’s staff of nationally renowned clinical pharmacists and interprofessional team work directly with caregivers, patients, and providers to ensure the most effective and safest medication therapy possible. For more information, visit: .

Forward-Looking Statements

This press release includes forward-looking statements that we believe to be reasonable as of today’s date. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 14, 2018, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.

Media Contact                      

Dianne Semingson                                                        

      

T: 215-870-0829                    

Investors

Bob East or Asher Dewhurst                                 

Westwicke Partners



T: 443-213-0500